StemCells (STEM) Posts Q3 Loss of 5c, Tops by 2c
More News related to STEM
- Emerging Healthcare in Discussions with Genetics Leader
- StemCells, Inc. Welcomes Approval of First Embryonic Stem Cell Lines Under New NIH Guidelines
- Unusual 11 Mid-Day Movers 12/02: ABCW, BIOF, GRH, STEM Higher; HEB, HDY, BGP, CBAK Lower
- NIH Approves 13 Stem-Cell Lines for Research; Watch STEM, ASTM, PSTI, CYTX, GERN on the News
- StemCells, Inc. CEO Martin McGlynn Featured On BioBusiness.TV's "Stem Cell Review" Series
More News related to Earnings
- NASB Financial (NASB) Posts Q4 EPS of $0.77, Tops Views
- Highlights From Take-Two Interactive Softwares' (TTWO) Forecast Teleconference
- Saks (SKS) Restates Q3 EPS to $0.04, Up from $0.01
- Big Lots (BIG) Delivers With Strong Q3 Results and Guidance
- Royal Bank Of Canada (RY) Posts Q4 EPS of CDN $1.06, Tops by 1c
StemCells Inc. (NASDAQ: STEM) reports Q3 loss of $0.05, 2 cents better than the analyst estimate of ($0.07). Revenue for the quarter was $253,000, which compares to the estimate of $180,000.
Related Categories
EarningsStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
